Navigation Links
TD2 and Critical Outcome Technologies Inc. develop novel anti-cancer drug
Date:1/12/2010

SCOTTSDALE, Ariz., and LONDON, Ontario Jan. 12, 2010 TGen Drug Development (TD2) and Critical Outcome Technologies Inc. (COTI) (TSXV:COT) announced today that they will work together to obtain approval of clinical trials for a promising new anti-cancer drug called COTI-2.

This easily synthesized small molecule compound was discovered and developed by COTI of London, Ontario, Canada. This working relationship resulted through the expanded relationship between Canadian companies and the Phoenix-based Translational Genomics Research Institute (TGen).

TD2, TGen's Scottsdale-based drug-development subsidiary, will work with COTI to complete the Investigational New Drug (IND) enabling research necessary to gain U.S. Food and Drug Administration approval of clinical trials, perhaps by the end of 2010, and eventually move the drug to market where it can benefit patients.

COTI-2 works by inducing a brisk apoptotic response the cancer cell kills itself by targeting a pro-survival enzyme family called AKT. Initial tests have shown that COTI-2 can limit the growth of tumors in several types of cancer without the toxic side effects seen in other AKT inhibitors. It also may be even more effective when used in combination with other anti-cancer drugs.

"While traditional cancer chemotherapy is frequently limited by significant toxic side effects, it is drug candidates like COTI-2 that represent a new generation of less toxic drugs with good anti-tumor activity," said Dr. Wayne Danter, COTI's President and Chief Scientific Officer.

COTI-2's development will be guided by Dr. Daniel Von Hoff, TGen's Physician-In-Chief and Senior Investigator of TGen's Clinical Translational Drug Division. Dr. Von Hoff has led the development of numerous successful cancer therapies. Dr. Von Hoff's biography can be found at www.tgen.org/research/index.cfm?pageid=77&peopleid=65.

"I am delighted about our participation in the continued development of this interesting new agent with what appears to be a highly desirable mechanism of action," said Dr. Von Hoff. "I am very hopeful that COTI-2 will have a therapeutic impact in patients with tumors that are non-responsive to conventional therapeutic agents across a number of cancer indications."

Researchers hope to demonstrate that this oral pill will be especially beneficial for patients with small-cell lung cancer (SCLC), endometrial cancer and ovarian cancer, but may also help treat those with colorectal and pancreatic cancers. Collectively, these treatments could represent a worldwide market of more than $20 billion by 2018.

"We are ready to move this exciting new agent to patients quickly and to identify patients most likely to benefit from COTI-2,'' said Dr. Steve Gately, TD2's President and Chief Scientific Officer.

"We are delighted to have the expertise of such a well respected individual as Dr. Von Hoff," said Mr. Michael Cloutier, Chief Executive Officer of COTI. "We believe that affiliating the development of COTI-2 with the scientific expertise of TD2 and Dr. Von Hoff will greatly assist in our commercial efforts. We value the partnership we have with TD2, which allows us to proceed with this program in a step wise fashion as resources become available."

The relationship between TD2 and COTI was initiated at BioPartnering North America 2008 thanks to the Canadian Consulate-Phoenix, which sponsored TGen's participation at the conference. The Canadian Consulate-Phoenix plays a key role in making strategic introductions across Arizona's universities, research facilities, local communities and commercial companies.

"I am thrilled to see this new drug development collaboration between TD2 and an emerging Canadian biotechnology company. The Canada Arizona Business Council hopes that many more will be done,'' said R. Glenn Williamson, Chief Executive Officer and Founder of the Canada Arizona Business Council.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. Self-seeding of cancer cells may play a critical role in tumor progression
2. Michael J. Fox Foundation Awards $1 Million for Critical Step Toward Development of Dyskinesia Treatments
3. CSTE National Assessment Finds Critical Public Health Disease Surveillance Capacity Lacking
4. Bullfrog Spas Helps Critically Ill Children
5. Coalition for Patients' Rights: Access to Broad Range of Health Care Providers Critical to Lowering Costs
6. Optimizing Corporate Culture is Critical to the Success of Wellness Programs
7. Study Finds Family Members Play Critical Role in Addressing Loved Ones' Hearing Loss
8. Crosstalk between critical cell-signaling pathways holds clues to tumor invasion and metastasis
9. New Jersey Soccer Coach Hopes for Thanksgiving Miracle for Local Mom - Tournament to Raise Funds for Her Critically Ill Baby
10. AARP Commends Legislature For Saving Critical Health Care Program
11. Protein critical for insulin secretion may be contributor to diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... practitioner, is known locally for a series of therapeutic sessions to help Los ... their characters and in their lives. The series, known as “Mindfulness for Actors ...
(Date:2/10/2016)... ... February 10, 2016 , ... MetLoop ... revolutionary new 2.0 version at the International Roofing Expo in Orlando, Florida on ... the world's most advanced weather technology in the hands of consumers, roofing contractors, ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Wickman Agency in Garland, ... the local community. Pledging to select a new beneficiary every 60 days, the ... Their goal is to bring community awareness to important local causes by forming ...
(Date:2/10/2016)... ... 2016 , ... Ongoing news of the ravages of traumatic brain injury (TBI) ... survey that takes a closer look at cases of TBI being managed by their ... TBI among the aging population, and identifies the challenges associated with their care. , ...
(Date:2/10/2016)... ... 10, 2016 , ... Armune BioScience signed a definitive agreement with ... service centers across the country. Launched in April of 2015, Apifiny is the only ... cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , Feb. 10, 2016  Visage Imaging ... Medicus Ltd. (ASX: PME), has announced that the American ... Florida (UF) have selected the Visage 7 Enterprise ... of the Emergent/Critical Care Imaging SIMulation (SIM). SIM ... Diagnostic Imaging Program (WIDI), a multi-faceted and fully-integrated ...
(Date:2/10/2016)... , February 10, 2016 CERS ), ... ADMS ) and Celldex Therapeutics, Inc. (NASDAQ: CLDX ... MDVN ), Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS ) and ... Today,s latest Orphan Drug Designations become vitally important in the ... to novel drugs and biologics which are defined as those ...
(Date:2/10/2016)... Israel , February 10, 2016 /PRNewswire/ ... leader in the field of cartilage repair, announces the ... 5, 2016. The $15 million investment was led by ... pharmaceutical manufacturer, and was joined by existing Regentis investors ... and both the Technion Research & Development Foundation and ...
Breaking Medicine Technology: